title: Thalidomide therapy and polyneuropathy in myeloma patients.
abstract: Thalidomide is today an increasingly used therapy in advanced and refractory myeloma patients, especially in patients relapsing after high dose therapy. One important and well-known side effect of thalidomide is polyneuropathy (PNP). The purpose of this study was to investigate 1) how severe the thalidomide-induced PNP is in patients treated for myeloma 2) which neurophysiological tests and parameters are most sensitive in detecting the thalidomide-induced PNP and 3) how neuropathic symptoms correlate with neurophysiological changes. Twelve patients received thalidomide for treatment of relapsed multiple myeloma for at least 5 months. Prior to the thalidomide treatment, all patients had been treated with chemotherapy including vincristine, and seven patients had also received cisplatin. PNP symptoms, clinical findings and neurophysiological tests before and after the therapy were evaluated. Prior to thalidomide treatment, 7 patients had minimal and one patient slight PNP. After thalidomide treatment, 4 patients had minimal, 4 patients slight, and 3 patients moderate PNP. Thalidomide-induced PNP mainly affected sensory myelinated axons, but also alpha motor neuron axons were affected to some extent. Thermal thresholds were not altered, indicating that thin myelinated and unmyelinated axons are spared. The most sensitive parameter for detecting thalidomide-induced PNP was the sensory nerve compound action potential amplitude. The neuropathic symptoms deteriorated significantly during the therapy, but clinically, no patient developed a disabling PNP that would have required interrupting the therapy. The neuropathic side effects of thalidomide seem to be acceptable in myeloma patients.
authors.affiliation: Department of Clinical Neurophysiology, Turku University Hospital, Turku, Finland. satu.laaksonen@tyks.fi
authors.forename: S
authors.initials: S
authors.lastname: Laaksonen
authors.forename: K
authors.initials: K
authors.lastname: Remes
authors.forename: K
authors.initials: K
authors.lastname: Koskela
authors.forename: L M
authors.initials: LM
authors.lastname: Voipio-Pulkki
authors.forename: B
authors.initials: B
authors.lastname: Falck
mesh_terms: D000200:Action Potentials; D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009475:Neurons, Afferent / Q000502:physiology; D011115:Polyneuropathies / Q000139:chemically induced*; D012720:Severity of Illness Index; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide